No BSE risk from vaccines, says PEI

13 February 2001

Commenting on a New York Times report that cattle residues fromcountries not declared BSE-free (including Germany) were used in the manufacture of nine vaccines, Johannes Loewer, head of the German vaccines and sera regulatory organization, the Paul Ehrlich Institute, has said that risk of transmission of BSE through vaccines is, at best, hypothetical.

Prof Loewer said agency reports that vaccines had been produced containing cattle cells were completely false and irresponsible. Sera from young calves or tissue or muscle extract were used in vaccine production but finished vaccine products did not contain them. The sole exception was milk-derived lactose used in vaccines against Hemophilus influenzae type B as a stabilizer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight